Table 1.
Serum KL-6 levels on admission and maximal KL-6 levels during the hospital stay in the nonsevere and severe illness groups and the survivor and nonsurvivor groups of patients with COVID-19.
| Nonsevere illness group (n = 296) |
Severe illness group (n = 60) |
p Value |
|
| KL-6 on admission | 255 (191–339) | 320 (235–564) | <0.001 |
| KL-6 maxa | 267 (203–364) | 549 (310–939) | <0.001 |
| ΔKL-6b |
37 (0–88) |
339 (118–488) |
<0.001 |
| Survivor group (n = 350) |
Nonsurvivor group (n = 6) |
p Value |
|
| KL-6 on admission | 259 (193–359) | 313 (288–666) | 0.083 |
| KL-6 maxa | 283 (207–417) | 1006 (764–1142) | 0.001 |
| ΔKL-6b | 64 (5–180) | 818 (607–1565) | 0.002 |
Data are presented as median (interquartile range).
KL-6, Krebs von den Lungen-6; COVID-19, coronavirus disease 2019.
a
KL-6 max: maximal KL-6 levels after admission.
b
ΔKL-6: difference in KL-6 levels between the values on admission and the maximal values.